BRAF and colorectal carcinoma: The phase III “Binimetinib, encorafenib, and cetuximab in BRAF600E-mutated CRC” (BEACON) trial showed the efficacy of another BRAF inhibitor, encorafenib, in dual-targeted EGFR and BRAF therapy as second-line systemic therapy for BRAFV600E-mutated CRC.